Is LYB a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Cycle recovery in polyolefins, with revenue (ttm) at ~$31.2B; Q2 2026 revenue ~$9.18B, up ~20% year over year. The bear case rests on lYB is deeply cyclical, so a prolonged glut in global petrochemical capacity, especially new supply from the Middle East and China, can keep polyolefin spreads compressed and earnings depressed. Analysts covering it are spread from $56.00 to $88.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. LYB is deeply cyclical, so a prolonged glut in global petrochemical capacity, especially new supply from the Middle East and China, can keep polyolefin spreads compressed and earnings depressed. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $56.00, -12.5% from the $64.01 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Cycle recovery in polyolefins. LYB's earnings are dominated by polyethylene and polypropylene spreads, which sat near cycle lows through 2025 and early 2026. The most optimistic analyst target on LYB is $88.00, +37.5% from the $64.01 price. That figure is only reachable if this thesis works close to its best case.

LYB is deeply cyclical, so a prolonged glut in global petrochemical capacity, especially new supply from the Middle East and China, can keep polyolefin spreads compressed and earnings depressed. The February 2026 dividend cut showed that the income is not guaranteed and can be reduced when markets stay weak. Feedstock and energy price swings, refining exit costs, foreign-currency exposure, and environmental and plastics-pollution litigation add further uncertainty. Trailing twelve-month GAAP net income is still about -$265 million because of 2025 losses, and analysts expect EPS to drop from about $9.10 in 2026 to about $6.20 in 2027, so the valuation leans on a recovery that may prove shorter than the Q2 2026 spike implied. Debt of about $14.3 billion against $2.65 billion of cash also limits flexibility. As a commodity producer, LYB has limited pricing power in downturns. The most pessimistic published target is $56.00, -12.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

LyondellBasell Industries is a Netherlands-domiciled, US-listed multinational and one of the largest plastics, chemicals, and refining companies in the world.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Cycle recovery in polyolefins) stalling in the reported numbers rather than in the narrative, the risk above (lYB is deeply cyclical, so a prolonged glut in global petrochemical capacity, especially new supply from the Middle East and China, can keep polyolefin spreads compressed and earnings depressed) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

LyondellBasell is one of the world's largest producers of plastics, chemicals, and refined products. It makes polyethylene and polypropylene (the raw materials for many plastics), plus chemical intermediates like propylene oxide and oxyfuels, and it historically operated a refinery it is now exiting.

LYB is generally viewed as a cyclical value and income stock rather than a growth stock. Its earnings rise and fall with commodity chemical spreads, so it trades on a low valuation multiple (about 10x forward earnings as of October 2026) and a mid-single-digit dividend yield instead of consistent revenue growth. The 2026 swing from losses to $4.30 of quarterly EPS shows that cyclicality clearly.

In February 2026 the board recalibrated the quarterly dividend to $0.69 per share, roughly halving it, citing challenged markets. Management framed it as a move to preserve balance-sheet strength through the downturn and to leave room to raise the payout again once conditions recover.